|  |  Ocular 
              Microbiology and Immunology Group
 Back 
              to OMIG Main Page
 2018 
            Agenda and Abstracts | < Previous Next > 
             2018 
            OMIG Abstract  
 In Vitro Synergy Testing Of Commonly Used Anti-Amoebic Agents:
 Antagonism Of Voriconazole
 
 Jeremy D Keenan, MD, MPH1,2, Maya Talbott, BS1, Vicky Cevallos, MT1,2, Michael C Chen2,
 Stephanie A Chin2, Lalitha Prajna3, Gerami D Seitzman, MD1,2, Thomas M Lietman, MD1,2
 1F.I. Proctor Foundation, San Francisco, CA, USA; 2Department of Ophthalmology, San Francisco, CA, USA; 3Aravind Eye Care System, Madurai, India
  Purpose:  Most ophthalmologists prescribe more than one anti-amoebic medication for Acanthamoeba keratitis, with a primary rationale being the potential for drug synergy. However, few studies have assessed the efficacy of combination anti-amoebic drug therapy. In this study, synergy testing was performed for the most commonly used anti-amoebic agents. Methods: Synergy testing for all combinations of chlorhexidine, propamidine, and voriconazole was performed with a microdilution checkerboard assayon 10 clinical acanthamoeba isolates collected at the Proctor Foundation from 2008-2012. Results:  Chlorhexidine and propamidine were cysticidal, with median minimum cysticidal concentrations (MCCs) of 12.5 (range 1.5 to 50) and 11.7 (range 0.2 to 250), respectively. Voriconazole was not cysticidal, with a median MCC of >10,000 µg/mL. The combination of chlorhexidine and propamidine did not markedly change the cysticidal activity compared to either drug alone. In contrast, voriconazole antagonized the cysticidal activity of both chlorhexidine and propamidine. Conclusion: In an in-vitro assay, voriconazole reduced the cysticidal activity of the most commonly used anti-amoebic drugs.While the in vivo drug interactions could be different, these observations may be useful in cases of non-healing acanthamoeba keratitis being treated with combination therapies including voriconazole. Disclosure: N Support: Research to Prevent Blindness, That Man May See   2018 
            Agenda and Abstracts | < Previous Next >     |  
 |